Acorda Buys Neurology Drug Developer Civitas Ahead Of IPO
This article was originally published in The Pink Sheet Daily
Executive Summary
Acorda gains an inhalable dry-powder version of levodopa, which it plans to move into a Phase III trial for the treatment of Parkinson’s disease in 2015, in exchange for $525 million in cash.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.